DMAA
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQFINANCIAL SERVICESSHELL COMPANIES
Key Statistics
Market Cap
$257.33M
P/E Ratio
53.00
EPS
$0.20
Beta
—
52W High
$10.61
52W Low
$10.12
50-Day MA
$10.54
200-Day MA
$10.39
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company dedicated to revolutionizing the U.S. pharmaceutical landscape through strategic collaborations with innovative firms. With a focus on enhancing domestic drug production and distribution, DMAA addresses pressing supply chain vulnerabilities and promotes the availability of affordable pharmaceuticals. By investing in cutting-edge technologies and fostering partnerships within the healthcare sector, DMAA is poised to significantly bolster local manufacturing, ultimately improving access to essential medications for consumers across the nation.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.21 |
| Price-to-Book | 1.10 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $24.28M |
| Float | $27.31M |
| % Insiders | 18.49% |
| % Institutions | 98.23% |
Historical Volatility
HV 10-Day
1.54%
HV 20-Day
2.24%
HV 30-Day
1.97%
HV 60-Day
2.38%
HV Rank
50.4%
Volatility is currently contracting
More FINANCIAL SERVICES Stocks
Data last updated: 5/25/2026